mProX™ Human MAP3K19 Stable Cell Line

Sub Cat	Product Name	Target Protein Species	Host Cell Type	Assay Types	Inquiry	Datasheet
S01YF-1222-KX531	Magic™ Human YSK4(MAP3K19) in Vitro Assay	Human		Kinase Assay

Product Information

Target Family

Kinases/Enzyme

Target Protein Species

Human

Host Cell Type

HEK293;CHO-K1;HeLa

Target Classification

Kinase Cell Lines

Target Research Area

Metabolic Research

Related Diseases

Diamond-Blackfan Anemia 1

Gene ID

Human:80122

UniProt ID

Human:Q56UN5

Product Properties

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

MAP3K19 is a gene that has been implicated in various diseases and conditions. In the context of congenital heart disease (CHD), a meta-analysis identified MAP3K19 as one of the novel candidate genes associated with CHD. The study found that MAP3K19 was upregulated in cardiomyocytes, suggesting its involvement in CHD pathogenesis. In the context of COVID-19, a study found that MAP3K19 regulatory variation in populations with African ancestry may increase the severity of the disease. The study revealed that a specific genetic variant of MAP3K19 was associated with reduced expression of the gene, which may contribute to the increased risk of severe COVID-19. In ovarian cancer, MAP3K19 was identified as a key target of CC chemokine 2 (CCL2) in promoting cancer progression. Knockout of MAP3K19 inhibited ovarian cancer cell proliferation, migration, and invasion. Additionally, in lung adenocarcinoma, a prognostic risk model based on an oxidative stress-related gene signature included MAP3K19 as one of the genes. The study showed that MAP3K19, along with another gene NTSR1, had clinical significance in identifying prognosis and guiding immunotherapy in lung adenocarcinoma patients. Lastly, in bicuspid aortic valve (BAV) patients, whole-exome sequencing identified MAP3K19 as one of the recurrent variants implicated in the disease. BAV patients carrying MAP3K19 variants showed reduced left ventricular ejection fractions and larger calcification volume, indicating its association with disease severity. Overall, MAP3K19 has been implicated in various diseases and conditions, highlighting its potential as a target for further research and therapeutic interventions.

Protocols

Please visit our protocols page.

Customer Reviews

There are currently no Customer reviews or questions for mProX™ Human MAP3K19 Stable Cell Line (S01YF-1023-PY136). Click the button above to contact us or submit your feedback about this product.

FAQ

chat Morgan Smith (Verified Customer)

What is the role of MAP3K19 in cancer? Mar 01 2020

chat Patrick Liam (Creative Biolabs Scientific Support)

MAP3K19 expression varies across different cancers and is correlated with patient survival, suggesting its potential as a therapeutic target. Mar 01 2020

chat Alex Smith (Verified Customer)

How does MAP3K19 contribute to pulmonary fibrosis? Jan 25 2021

chat Patrick Liam (Creative Biolabs Scientific Support)

MAP3K19 promotes the progression of tuberculosis-induced pulmonary fibrosis through the TGF-β/Smad2 signaling pathway. Jan 25 2021

Published Data

Fig.1 MAP3K19 facilitated the nuclear translocation of phosphorylated R-Smads, specifically phospho-Smad2 and phospho-Smad3, in response to TGF-β1 stimulation, aiding in their cellular localization.

HeLa cells were subjected to transfection with either nonsense siRNA (at doses of 250 or 500 ng) or MAP3K19 siRNA (at doses of 250 or 500 ng). Subsequently, after an 18-hour incubation, the cells were exposed to TGF-β1 (at a concentration of 1 ng/ml) for a duration of 1 hour. Following this treatment, cell samples were collected, and nuclear extracts were isolated. Western analysis was performed on these nuclear lysates to assess the levels of P-Smad2, P-Smad3, and Smad4, with additional probing for HDAC-1 to confirm uniform protein loading. Densitometry analysis was conducted to compare the ratios of P-Smad2/HDAC-1 and P-Smad3/HDAC-1 levels. Smad4 levels were excluded from densitometry analysis as they remained unaffected. This experimental procedure was repeated three times independently, and a representative instance is presented.

Ref: Boehme, Stefen A., et al. "MAP3K19 is a novel regulator of TGF-β signaling that impacts bleomycin-induced lung injury and pulmonary fibrosis." PloS one 11.5 (2016): e0154874.

Pubmed: 27144281

DOI: 10.1371/journal.pone.0154874

Research Highlights

Tambi, Richa. et al. "Single-Cell Reconstruction and Mutation Enrichment Analysis Identifies Dysregulated Cardiomyocyte and Endothelial Cells in Congenital Heart Disease." Physiological genomics, 2023.
In this study, the prevalence of congenital heart disease (CHD) in neonates was examined. A total of 16,349 variants, including single nucleotide variants (SNVs) and Indels, were collected from 3,166 CHD cases representing 8,308 genes. The researchers utilized ACMG guidelines to exclude 0.1% of benign/likely benign variants, resulting in a dataset consisting of 83% predicted loss of function variants and 17% missense variants. Of note, 17% of the variants were found to be potentially pathogenic based on ACMG criteria.
Tambi, Richa. et al. "Single-Cell Reconstruction and Mutation Enrichment Analysis Identifies Dysregulated Cardiomyocyte and Endothelial Cells in Congenital Heart Disease." Physiological genomics, 2023.
Pubmed: 37811720 DOI: 10.1152/physiolgenomics.00070.2023

Cheng, Zhongshan. et al. "MAP3K19 regulatory variation in populations with African ancestry may increase COVID-19 severity." iScience, 2023.
In order to identify genetic risk variants associated with COVID-19 hospitalization, an integrative analysis of two genome-wide association studies was conducted. This analysis revealed four single nucleotide polymorphisms that were more prevalent in COVID-19-hospitalized patients with non-European ancestry. Of these, the COVID-19 risk SNP rs16831827 exhibited the largest difference in minor allele frequency (MAF) between populations of African and European ancestry. Furthermore, this SNP was found to have a higher MAF in hospitalized COVID-19 patients from cohorts of both mixed and entirely African ancestry (OR = 1.20, 95% CI: 1.10-1.30 and OR = 1.30, 95% CI: 1.02-1.67, respectively). Additionally, rs16831827 is an expression quantitative trait locus for seven genes, most notably TSLP.
Cheng, Zhongshan. et al. "MAP3K19 regulatory variation in populations with African ancestry may increase COVID-19 severity." iScience, 2023.
Pubmed: 37649700 DOI: 10.1016/j.isci.2023.107555